Our priorities at this challenging time are the well-being of our staff and their families, and of the clinical staff and patients in our clinical trials. We are monitoring the Covid-19 pandemic situation in each of the countries in which we operate and complying with local/national directives. The vast majority of our staff are able to work from their homes and, where possible, travel has been stopped.
We are making every effort to minimize the impact on our business and our clients’ projects. Our project managers are keeping their clients updated on the challenges and solutions in their respective projects. In many cases monitoring visits to clinical facilities have been suspended for the time being; these have been replaced by remote monitoring and critical data review, with non-essential activities being postponed. We want to assure our clients that we have robust business continuity plans in place, that we are adequately staffed and that we remain focused on their projects. As soon as we can be up and running normally again we will we will be doing our best to recover from this challenge.
With my best wishes to all,
Malgosia Szerszeniewska, CEO